The funds will be used to promote clinical research in the existing pipeline, expand professional teams and develop innovative drugs.
Inhalation Formulation Developer Resproly (Chinese: 瑞思普利) recently received over CNY 100 million (USD 15.14 million) from Qianhai FOF and Fuho Capital in Series B+ financing round.
Previously in February 2021, it completed a nearly CNY 200 million Series B financing round led by CAS Investment; YuanBio Venture Capital, Cowin Capital, Qianhai FOF, Tianfeng Capital and Efung Capital also took apart.
Founded in 2018 and headquartered in Shenzhen, Resproly focuses on the respiratory system inhalation drug formulation technology and devices. The company currently has four R&D and production platforms for metered dose inhalation (MDI), dry powder inhalation (DPI), nebulizer and nasal spray.
Products under development involve multiple therapeutic areas with high clinical needs, including asthma, chronic obstructive pulmonary disease, diabetes, and Parkinson's disease.
Resproly's first imitation product RSG0101 will complete the BE filing this year and then enter the clinical stage, sources said, which is expected to launch in 2023 at the earliest. In addition, the company plans to advance two other premium inhalation formulations into clinical trials in 2022.
“Resproly has a presence in the field of premium inhalation formulations domestically, and the company's technology platform and R&D pipeline are also iteratively upgraded. We believe that Resproly will bring excellent returns to investors and create huge economic and social value," said Dr. Chen Yongqi, chairman of Resproly.
Dr. Duan Xufang, executive director of Qianhai FOF, said,“we highly value Dr. Chen's extensive experience in the field of inhalation formulations, as well as his progressive Resproly. We Qianhai FOF will continuously support the company for the future betterment.”
The domestic competitors of Resproly include CF Pharmtech, Chiatai Tianqing, Joincare (600380.SH), Sichuan Purity and OMNI Pharma.